Efficacy of rituximab in primary immune thrombocytopenia: an
analysis of adult pretreated patients from everyday
hematological practice

J 2012

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice

ČERVINEK, Libor, Olga CERNA, Miroslav ČANIGA, Eva KONIROVA, Antonín HLUŠÍ et. al.

Základní údaje

Originální název

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice

Autoři

ČERVINEK, Libor (203 Česká republika, garant, domácí), Olga CERNA (203 Česká republika), Miroslav ČANIGA (203 Česká republika), Eva KONIROVA (203 Česká republika), Antonín HLUŠÍ (203 Česká republika), Martin SIMKOVIC (203 Česká republika), Zdeněk POSPÍŠIL (203 Česká republika, domácí), Jaroslav CERMAK (203 Česká republika), Tomáš KOZÁK (203 Česká republika), Jiří MAYER (203 Česká republika, domácí) a Michael DOUBEK (203 Česká republika, domácí)

Vydání

International journal of hematology, Tokyo, Japan, Springer, 2012, 0925-5710

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Japonsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.681

Kód RIV

RIV/00216224:14740/12:00058699

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1007/s12185-012-1206-7

UT WoS

000311518300010

Klíčová slova anglicky

Adults; Immune thrombocytopenia; Response rate; Rituximab

Štítky

ok, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 4. 2013 14:40, Olga Křížová

Anotace

V originále

Although rituximab has seen increasing use in the treatment of immune thrombocytopenia (ITP) for many years, its therapeutic role in this disease remains unclear. We retrospectively analyzed data of all patients with ITP treated with rituximab (375 mg/m(2) once weekly for four consecutive weeks) and consecutively entered the findings into the databases of six large academic centers in the Czech Republic. A total of 114 patients were included in the analysis. All of the patients received rituximab as a second or additional line of therapy. The overall response rate (ORR) after rituximab therapy was 72 % [48 % complete response (CR), 24 % partial response (PR)] at month 6, and 69 % (45 % CR, 24 % PR) at month 12. For the group of patients with newly diagnosed (acute) ITP, the results of treatment were significantly better than for the group of patients with persistent or chronic ITP; nonetheless, this group of patients was far too small (n = 18) for our findings to be generalized. Multivariate analysis revealed that the ORR was significantly influenced primarily by the number of therapies prior to rituximab (the more previous therapies, the worse treatment response). The results of our analysis "from everyday hematological practice" confirm the high efficiency of rituximab treatment in pretreated adult patients with ITP.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

EE2.3.20.0045, projekt VaV

Název: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny

FR-TI2/254, projekt VaV

Název: *Real-time PCR soupravy pro diagnostiku v onkologii (Akronym: ONKOKITY)

Investor: Ministerstvo průmyslu a obchodu ČR, Real-time PCR soupravy pro diagnostiku v onkologii

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Přiložené soubory

download.pdf

Požádat o autorskou verzi souboru

Citovat

ČERVINEK, Libor, Olga CERNA, Miroslav ČANIGA, Eva KONIROVA, Antonín HLUŠÍ, Martin SIMKOVIC, Zdeněk POSPÍŠIL, Jaroslav CERMAK, Tomáš KOZÁK, Jiří MAYER a Michael DOUBEK. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. International journal of hematology. Tokyo, Japan: Springer, 2012, roč. 96, č. 5, s. 594-599. ISSN 0925-5710. Dostupné z: https://dx.doi.org/10.1007/s12185-012-1206-7.

@article{1079733,
   author = {Červinek, Libor and Cerna, Olga and Čaniga, Miroslav and Konirova, Eva and Hluší, Antonín and Simkovic, Martin and Pospíšil, Zdeněk and Cermak, Jaroslav and Kozák, Tomáš and Mayer, Jiří and Doubek, Michael},
   article_location = {Tokyo, Japan},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s12185-012-1206-7},
   keywords = {Adults; Immune thrombocytopenia; Response rate; Rituximab},
   language = {eng},
   issn = {0925-5710},
   journal = {International journal of hematology},
   title = {Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice},
   url = {http://link.springer.com/content/pdf/10.1007%2Fs12185-012-1206-7},
   volume = {96},
   year = {2012}
}

TY  - JOUR
ID  - 1079733
AU  - Červinek, Libor - Cerna, Olga - Čaniga, Miroslav - Konirova, Eva - Hluší, Antonín - Simkovic, Martin - Pospíšil, Zdeněk - Cermak, Jaroslav - Kozák, Tomáš - Mayer, Jiří - Doubek, Michael
PY  - 2012
TI  - Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice
JF  - International journal of hematology
VL  - 96
IS  - 5
SP  - 594-599
EP  - 594-599
PB  - Springer
SN  - 09255710
KW  - Adults
KW  - Immune thrombocytopenia
KW  - Response rate
KW  - Rituximab
UR  - http://link.springer.com/content/pdf/10.1007%2Fs12185-012-1206-7
L2  - http://link.springer.com/content/pdf/10.1007%2Fs12185-012-1206-7
N2  - Although rituximab has seen increasing use in the treatment of immune thrombocytopenia (ITP) for many years, its therapeutic role in this disease remains unclear. We retrospectively analyzed data of all patients with ITP treated with rituximab (375 mg/m(2) once weekly for four consecutive weeks) and consecutively entered the findings into the databases of six large academic centers in the Czech Republic. A total of 114 patients were included in the analysis. All of the patients received rituximab as a second or additional line of therapy. The overall response rate (ORR) after rituximab therapy was 72 % [48 % complete response (CR), 24 % partial response (PR)] at month 6, and 69 % (45 % CR, 24 % PR) at month 12. For the group of patients with newly diagnosed (acute) ITP, the results of treatment were significantly better than for the group of patients with persistent or chronic ITP; nonetheless, this group of patients was far too small (n = 18) for our findings to be generalized. Multivariate analysis revealed that the ORR was significantly influenced primarily by the number of therapies prior to rituximab (the more previous therapies, the worse treatment response). The results of our analysis "from everyday hematological practice" confirm the high efficiency of rituximab treatment in pretreated adult patients with ITP.
ER  -

ČERVINEK, Libor, Olga CERNA, Miroslav ČANIGA, Eva KONIROVA, Antonín HLUŠÍ, Martin SIMKOVIC, Zdeněk POSPÍŠIL, Jaroslav CERMAK, Tomáš KOZÁK, Jiří MAYER a Michael DOUBEK. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. \textit{International journal of hematology}. Tokyo, Japan: Springer, 2012, roč.~96, č.~5, s.~594-599. ISSN~0925-5710. Dostupné z: https://dx.doi.org/10.1007/s12185-012-1206-7.

Přehled o publikaci